

the subsequence is the extracellular domain of SEQ ID NO:66, and wherein the isolated or recombinant polypeptide has a human CD28/human CTLA-4 binding affinity ratio about equal to or greater than the human CD28/human CTLA-4 binding affinity ratio of human B7-1 when expressed on a cell or bound to a cell membrane.

260. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide is expressed on a cell or bound to a cell membrane.

261. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide comprises an extracellular domain which comprises an amino acid sequence having at least about 95% sequence identity to the extracellular domain of SEQ ID NO:66, wherein said extracellular domain of SEQ ID NO:66 comprises at least amino acid residues 35-244 of SEQ ID NO:66.

262. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide comprises an extracellular domain which comprises an amino acid sequence having at least about 95% sequence identity to the extracellular domain of SEQ ID NO:66, wherein the extracellular domain of SEQ ID NO:66 comprises at least amino acid residues 35-245 of SEQ ID NO:66.

263. (New) The isolated or recombinant polypeptide of claim 261, wherein the polypeptide comprises an extracellular domain comprising at least amino acid residues 35-244 of SEQ ID NO:66.

264. (New) The isolated or recombinant polypeptide of claim 261, wherein the polypeptide comprises an extracellular domain comprising at least amino acid residues 35-244 of SEQ ID NO:66.

264. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide further comprises a signal peptide.

265. (New) The isolated or recombinant polypeptide of claim 264, wherein the signal peptide comprises an amino acid sequence that has at least about 90% sequence identity to the amino acid sequence comprising residues 1-34 of SEQ ID NO:66.

266. (New) The isolated or recombinant polypeptide of claim 264, wherein the signal peptide has an amino acid sequence comprising amino acid residues 1-34 of SEQ ID NO:66.

267. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide comprises a transmembrane domain.

B1
cont

268. (New) The isolated or recombinant polypeptide of claim 267, wherein the polypeptide comprises the transmembrane domain of SEQ ID NO:66.

269. (New) The isolated or recombinant polypeptide of claim 268, wherein the transmembrane domain comprises an amino acid sequence having at least about 90% sequence identity to an amino acid sequence comprising at least amino acid residues 245-268 or 246-272 of SEQ ID NO:66.

270. (New) The isolated or recombinant polypeptide of claim 269, wherein the transmembrane domain comprises an amino acid sequence comprising at least amino acid residues 245-268 or 246-272 of SEQ ID NO:66.

271. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide further comprises a cytoplasmic domain.

272. (New) The isolated or recombinant polypeptide of claim 271, wherein the polypeptide comprises the cytoplasmic domain of SEQ ID NO:66.

273. (New) The isolated or recombinant polypeptide of claim 271, wherein the cytoplasmic domain comprises an amino acid sequence having at least about 90% sequence identity to an amino acid sequence comprising at least amino acid residues 269-303 or 273-303 of SEQ ID NO:66.

274. (New) The isolated or recombinant polypeptide of claim 273, wherein the cytoplasmic domain comprises an amino acid sequence comprising at least amino acid residues 269-303 or 273-303 of SEQ ID NO:66.

275. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence comprising a mature domain of SEQ ID NO:66.

276. (New) The isolated or recombinant polypeptide of claim 275, wherein the mature domain comprises amino acid residues 35-303 of SEQ ID NO:66.

277. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence corresponding to the signal peptide, extracellular domain and transmembrane domain of SEQ ID NO:66 which comprises at least amino acid residues 1-268 or 1-272 of SEQ ID NO:66.

B)
cont

278. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide has at least about 91% sequence identity to the full length amino acid sequence of SEQ ID NO:66.

279. (New) The isolated or recombinant polypeptide of claim 278, wherein the polypeptide comprises the full length amino acid sequence of SEQ ID NO:66.

280. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide has a human CD28/human CTLA-4 binding affinity ratio greater than the human CD28/human CTLA-4 binding affinity ratio of human B7-1.

281. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide has a binding affinity for CD28 that is at least about equal to or greater than the binding affinity of human B7-1 for CD28.

282. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide has a binding affinity for CTLA-4 that is less than the binding affinity of human B7-1 for CTLA-4.

283. (New) The isolated or recombinant polypeptide of claim 259, wherein the polypeptide has an ability to induce a T-cell proliferation response about equal to or greater than the T-cell proliferation response induced by human B7-1.

284. (New) An isolated or recombinant polypeptide comprising an extracellular domain, said extracellular domain comprising an amino acid sequence having at least about 91% sequence identity to a subsequence of SEQ ID NO:66, said subsequence comprising at least amino acid residues 35-244 or 35-245 of SEQ ID NO:66, wherein said polypeptide induces a T-cell proliferation response about equal to or greater than the T-cell proliferation response induced by human B7-1 when expressed on a cell or bound to a cell membrane.

285. (New) The isolated or recombinant polypeptide of claim 284, wherein the subsequence comprises at least amino acid residues 35-245 of SEQ ID NO:66.

286. (New) The isolated or recombinant polypeptide of claim 284, wherein the polypeptide comprises one or more of a signal peptide, transmembrane domain, and cytoplasmic domain.

287. (New) The isolated or recombinant polypeptide of claim 286, wherein the polypeptide comprises an amino acid sequence having at least about 95% sequence identity to the full length amino acid sequence of SEQ ID NO:66.

B1
cont

288. (New) The isolated or recombinant polypeptide of claim 259, wherein the cell is an antigen-presenting cell.

289. (New) The polypeptide of claim 259, comprising at least one modified amino acid.

290. (New) The polypeptide of claim 288, wherein the modified amino acid is selected from: a glycosylated amino acid, a PEGylated amino acid, a farnesylated amino acid, an acetylated amino acid, a biotinylated amino acid, an amino acid conjugated to a lipid moiety, and an amino acid conjugated to an organic derivatizing agent.

291. (New) An isolated or recombinant polypeptide comprising an amino acid sequence according to the formula:

MGHTM-X6-W-X8-SLPPK-X14-PCL-X18-X19-X20-QLLVLT-X27-LFYFCSGITPKSVTKRVKETVMLSCDY-X55-TSTE-X60-LTSLRIYW-X69-KDSKMLVAILPGKVQVWPEYKNRTITDMNDN-X101-RIVI-X106-ALR-X110-SD-X113-GTYTCV-X120-QKP-X124-LKGAYKLEHL-X135-SVRLMIRADFPVP-X149-X150-X151-DLGNPSNIRRLICS-X167-X168-X169-GFPRPHL-X177-WLENGEELNATNTT-X192-SQDP-X197-T-X199-LYMISSSEL-X208-FNVTNN-X215-SI-X218-CLIKYGEL-X227-VSQIFPWSKPKQEPPIDQLPF-X249-VIIPVSGALVL-X261-A-X263-VLY-X267-X268-ACRH-X273-ARWKRRTRNEETVGTE RLSPYILGSAQSSG, or an extracellular domain subsequence thereof comprising amino acid residues at positions 35-244,

wherein the amino acid residue at position X6 is Lys or Glu; position X8 is Arg or Gly; position X14 is Arg or Cys; position X18 is Trp or Arg; position X19 is Pro or Leu; position X20 is Ser or Pro; position X27 is Asp or Gly; position X55 is Asn or Ser; position X60 is Glu or Lys; position X69 is Gln or Arg; position X101 is Pro or Leu; position X106 is Leu or Gln; position X110 is Pro or Leu; position X113 is Lys or Ser; position X120 is Val or Ile; position X124 is Val or Asp; position X135 is Thr or Ala; position X149 is Thr, Ser, or deleted; position X150 is Ile or deleted; position X151 is Asn or Thr; position X167 is Thr or deleted; position X169 is Ser or deleted; position X169 is Gly or deleted; position X177 is Cys or Tyr; position X192 is Val or Leu; position X197 is Gly or Glu; position X199 is Glu or Lys; position X208 is Gly or Asp; position X215 is His or Arg; position X218 is Ala or Val; position X227 is Ser or Leu; position X249 is Trp, Leu, or Arg; position X261 is Ala or Thr; position X263 is Val, Ala, or Ile; position X267 is Arg or Cys; position X268 is Pro or Leu; and position X273 is Gly or Val, and

B)
cont

wherein the polypeptide has a human CD28/human CTLA-4 binding affinity ratio about equal to or greater than the human CD28/human CTLA-4 binding affinity ratio of human B7-1 and/or induces a T-cell proliferation or activation response when expressed on a cell or bound to a cell membrane.

292. (New) The isolated or recombinant polypeptide of claim 291, wherein the polypeptide has a human CD28/human CTLA-4 binding affinity ratio about greater than the human CD28/human CTLA-4 binding affinity ratio of human B7-1.

293. (New) The isolated or recombinant polypeptide of claim 291, wherein the polypeptide induces a T-cell proliferation response about equal to or greater than that induced by human B7-1.

294. (New) The isolated or recombinant polypeptide of claim 291, comprising three or more of: Lys at position X6; Arg at position X8; Arg at position X14; Trp at position X18; Pro at position X19; Ser at position X20; Asp at position X27; Asn at position X55; Leu at position X106; Pro at position X110; Lys at position X113; Val at position X120; Val at position X124; Thr at position X135; Asn at position X151; Cys at position X177; Val at position X192; Gly at position X197; Glu at position X199; Gly at position X208; His at position X215; Ala at position X218; Trp at position X249; Ala at position X261; Val at position X263; Arg at position X267; Pro at position X268; and Gly at position X273.

295. (New) The isolated or recombinant polypeptide of claim 294, comprising three or more of: Arg at position X8; Arg at position X14; Trp at position X18; Pro at position X19; Ser at position X20; Pro at position X110; Val at position X120; Val at position X124; Cys at position X177; Val at position X192; Gly at position X197; Glu at position X199; Gly at position X208; His at position X215; Ala at position X218; Trp at position X249; Ala at position X261; and Val at position X263.

296. (New) The isolated or recombinant polypeptide of claim 295, comprising amino acid residues 35-244 of SEQ ID NO:66.

297. (New) An isolated or recombinant polypeptide comprising an amino acid sequence having at least about 91% sequence identity to the complete amino acid sequence set forth in SEQ ID NO:66, wherein said polypeptide when expressed on a cell or bound to a cell membrane has a human CD28/human CTLA-4 binding affinity ratio at least about equal to the human

B1
cont

CD28/human CTLA-4 binding affinity ratio of human B7-1 or induces a T-cell proliferation or activation response.

298. (New) A composition comprising a polypeptide of claim 259 and a pharmaceutically acceptable excipient.

299. (New) An isolated or recombinant polypeptide comprising an amino acid sequence comprising at least amino acid residues 245-268 or 246-272 of SEQ ID NO:66.

300. (New) An isolated or recombinant polypeptide comprising an amino acid sequence comprising at least amino acid residues 269-303 or 273-303 of SEQ ID NO:66.

301. (New) The isolated or recombinant polypeptide of claim 264, wherein the polypeptide comprises an amino acid sequence comprising at least amino acid residues 1-244 or 1-245 of SEQ ID NO:66.

(B)
cont

302. (New) An isolated or recombinant nucleic acid comprising a polynucleotide sequence that encodes a polypeptide comprising an extracellular domain, said extracellular domain comprising an amino acid sequence having at least about 91% sequence identity to a subsequence of the polypeptide sequence set forth in SEQ ID NO:66, wherein the subsequence is the extracellular domain of SEQ ID NO:66, and wherein the encoded polypeptide has a human CD28/human CTLA-4 binding affinity ratio about equal to or greater than the human CD28/human CTLA-4 binding affinity ratio of human B7-1 or induces a T-cell proliferation or activation response when expressed on a cell or bound to a cell membrane, or a complementary polynucleotide sequence thereof.

303. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide is expressed on a cell or bound to a cell membrane.

304. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide comprises an extracellular domain comprising an amino acid sequence having at least about 95% sequence identity to the amino acid sequence comprising at least amino acid residues 35-244 of SEQ ID NO:66.

305. (New) The isolated or recombinant nucleic acid of claim 304, wherein the encoded polypeptide comprises an extracellular domain comprising at least amino acid residues 35-244 or 35-245 of SEQ ID NO:66.

306. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide comprises a signal peptide.

307. (New) The isolated or recombinant nucleic acid of claim 306, wherein the signal peptide comprises the signal peptide of human B7-1.

308. (New) The isolated or recombinant nucleic acid of claim 307, wherein the signal peptide comprises an amino acid sequence comprising amino acid residues 1-34 of SEQ ID NO:66.

309. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide comprises a transmembrane domain.

310. (New) The isolated or recombinant nucleic acid of claim 309, wherein the transmembrane domain comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence comprising at least amino acid residues 245-268 or 246-272 of SEQ ID NO:66.

311. (New) The isolated or recombinant nucleic acid of claim 309, wherein the transmembrane domain comprises an amino acid sequence having at least about 95% sequence identity to the amino acid sequence comprising at least amino acid residues 245-268 or 246-272 of SEQ ID NO:66.

(B)
cont
312. (New) The isolated or recombinant nucleic acid of claim 311, wherein the transmembrane domain comprises an amino acid sequence comprising at least amino acid residues 245-268 or 246-272 of SEQ ID NO:66.

313. (New) The isolated or recombinant polypeptide of claim 309, wherein the polypeptide comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence corresponding to the extracellular domain and transmembrane domain of SEQ ID NO:66 which comprises at least amino acid residues 35-268 or 35-272 of SEQ ID NO:66.

314. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide further comprises a cytoplasmic domain.

315. (New) The isolated or recombinant nucleic acid of claim 314, wherein the cytoplasmic domain comprises an amino acid sequence having at least about 90% sequence identity to the amino acid sequence comprising at least amino acid residues 269-303 or 273-303 of SEQ ID NO:66.

316. (New) The isolated or recombinant nucleic acid of claim 315, wherein the cytoplasmic domain comprises an amino acid sequence at least comprising at least amino acid residues 269-303 or 273-303 of SEQ ID NO:66.

317. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide comprises an amino acid sequence having at least about 95% sequence identity to the amino acid sequence comprising at least amino acid residues 35-303 of SEQ ID NO:66.

318. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide comprises an amino acid sequence having at least about 95% sequence identity to the amino acid sequence comprising at least amino acid residues 35-268 or 35-272 of SEQ ID NO:66.

319. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide comprises an amino acid sequence having at least about 95% sequence identity to the amino acid sequence comprising at least amino acid residues 1-268 or 1-272 of SEQ ID NO:66.

320. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide has at least about 95% sequence identity to the full length amino acid sequence of SEQ ID NO:66.

321. (New) The isolated or recombinant nucleic acid of claim 302, wherein the polynucleotide sequence is selected from the group consisting of:

(a) a polynucleotide sequence encoding the full length amino acid sequence set forth in SEQ ID NO:66;

(b) the polynucleotide sequence set forth in SEQ ID NO:19;

(c) a polynucleotide sequence that, but for the degeneracy of the genetic code, hybridizes under at least stringent conditions to the complement of the polynucleotide sequence of (a) or (b); and

(d) a polynucleotide sequence complementary to the polynucleotide sequence of (a) or (b).

322. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide has a human CD28/human CTLA-4 binding affinity ratio greater than the human CD28/human CTLA-4 binding affinity ratio of human B7-1 and/or induces a T-cell proliferation or activation response about equal to or greater than that induced by human B7-1.

323. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide has a binding affinity for human CD28 that is at least about equal to or greater than the binding affinity of human B7-1 for human CD28.

B1
cont

324. (New) The isolated or recombinant nucleic acid of claim 302, wherein the encoded polypeptide has a binding affinity for human CTLA-4 that is less than the binding affinity of human B7-1 for human CTLA-4.

325. (New) An isolated or recombinant nucleic acid comprising a polynucleotide sequence that has at least about 90% sequence identity to a nucleotide sequence encoding an extracellular domain, said nucleotide sequence comprising at least nucleic acid residues 103-732 of SEQ ID NO:19, wherein said nucleic acid encodes a polypeptide that has a human CD28/human CTLA-4 binding affinity ratio about equal to or greater than the human CD28/human CTLA-4 binding affinity ratio of human B7-1 and/or induces a T-cell proliferation or activation response when expressed on a cell or bound to a cell membrane, or a complementary polynucleotide sequence thereof.

326. (New) The isolated or recombinant nucleic acid of claim 325, wherein the polynucleotide sequence comprises at least nucleic acid residues 103-732 or 103-735 of SEQ ID NO:19, or a complementary polynucleotide sequence thereof.

327. (New) The isolated or recombinant nucleic acid of claim 325, further comprising a nucleotide sequence encoding a signal peptide.

328. (New) The isolated or recombinant nucleic acid of claim 327, wherein the signal peptide is encoded by a nucleotide sequence selected from the group of:

(a) a nucleotide sequence comprising nucleic acid residues 1-102 of SEQ ID NO:19, or a complementary nucleotide sequence thereof;

(b) a nucleotide sequence that encodes amino acid residues 1-34 of SEQ ID NO:66, or a complementary nucleotide sequence thereof; and

(c) a nucleotide sequence which, but for the degeneracy of the genetic code, hybridizes under at least stringent conditions to substantially the entire length of a polynucleotide sequence (a) or (b).

329. (New) The isolated or recombinant nucleic acid of claim 325, further comprising a nucleotide sequence encoding a transmembrane domain.

330. (New) The isolated or recombinant nucleic acid of claim 329, further comprising a nucleotide sequence encoding the transmembrane domain of SEQ ID NO:66.

331. (New) The isolated or recombinant nucleic acid of claim 330, wherein the transmembrane domain is encoded by a nucleotide sequence selected from the group of:

B)
cont

(a) a nucleotide sequence comprising at least nucleic acid residues 733-804 or 736-816 of SEQ ID NO:19, or a complementary nucleotide sequence thereof;

(b) a nucleotide sequence that encodes at least amino acid residues 245-268 or 246-272 of SEQ ID NO:66, or a complementary nucleotide sequence thereof; and

(c) a nucleotide sequence which, but for the degeneracy of the genetic code, hybridizes under at least stringent conditions to substantially the entire length of a polynucleotide sequence of (a) or (b).

332. (New) The isolated or recombinant nucleic acid of claim 325, further comprising a nucleotide sequence encoding a cytoplasmic domain.

333. (New) The isolated or recombinant nucleic acid of claim 332, comprising a nucleotide sequence encoding a cytoplasmic domain of SEQ ID NO:66.

334. (New) The isolated or recombinant nucleic acid of claim 333, wherein the cytoplasmic domain is encoded by a nucleotide sequence selected from the group of:

(a) a nucleotide sequence comprising at least nucleic acid residues 734-909 or 817-909 of SEQ ID NO:19, or a complementary nucleotide sequence thereof;

(b) a nucleotide sequence that encodes amino acid residues 269-303 or 273-303 of SEQ ID NO:66, or a complementary nucleotide sequence thereof; and

(c) a nucleotide sequence which, but for the degeneracy of the genetic code, hybridizes under at least stringent conditions to substantially the entire length of a polynucleotide sequence of (a) or (b).

335. (New) The isolated or recombinant nucleic acid of claim 325, wherein the encoded polypeptide has a human CD28/human CTLA-4 binding affinity ratio greater than the human CD28/human CTLA-4 binding affinity ratio of human B7-1.

336. (New) The isolated or recombinant nucleic acid of claim 325, wherein the encoded polypeptide induces a T-cell proliferation or activation response about equal to or greater than that induced by human B7-1.

337. (New) The isolated or recombinant nucleic acid of claim 325, wherein the polynucleotide sequence has at least about 90% sequence identity to a nucleotide sequence comprising at least nucleic acid residues 1-732 of SEQ ID NO:19, or a complementary polynucleotide sequence thereof.

(B)
cont

338. (New) The isolated or recombinant nucleic acid of claim 325, wherein the encoded polypeptide comprises a signal peptide, extracellular domain, and transmembrane domain, and the polynucleotide sequence has at least about 90% sequence identity to a nucleotide sequence comprising at least nucleic acid residues 1-804 or 1-816 of SEQ ID NO:19, or a complementary polynucleotide sequence thereof.

339. (New) The isolated or recombinant nucleic acid of claim 325, wherein the encoded polypeptide comprises an extracellular domain, transmembrane domain, and cytoplasmic domain, and the polynucleotide sequence has at least about 90% sequence identity to a nucleotide sequence comprising at least nucleic acid residues 103-912 of SEQ ID NO:19, or a complementary polynucleotide sequence thereof.

340. (New) The isolated or recombinant nucleic acid of claim 325, wherein the polynucleotide sequence has at least about 90% sequence identity to the nucleotide sequence set forth in SEQ ID NO:19, or a complementary polynucleotide sequence thereof.

341. (New) A composition comprising a nucleic acid of claim 302 and an excipient.

342. (New) The composition of claim 341, wherein the excipient is a pharmaceutically acceptable excipient.

343. (New) A composition comprising a nucleic acid of claim 325 and an excipient.

344. (New) The composition of claim 343, wherein the excipient is a pharmaceutically acceptable excipient.

345. (New) A cell comprising a nucleic acid of claim 302.

346. (New) A cell comprising a nucleic acid of claim 325.

347. (New) A cell comprising a polypeptide of claim 259.

348. (New) A vector comprising a nucleic acid of claim 302.

349. (New) The vector of claim 348, wherein the vector comprises a plasmid, a cosmid, a phage, a virus, a virus particle, or a fragment of a virus.

350. (New) The vector of claim 348, wherein the vector is an expression vector.

351. (New) The vector of claim 350, wherein the nucleic acid is operably linked to a promoter.

B1
cont

352. (New) The vector of claim 350, wherein the vector further comprises a polynucleotide sequence encoding an antigen.

353. (New) The vector of claim 352, wherein the nucleic acid is operably linked to first promoter and the polynucleotide sequence encoding the antigen is operably linked to a second promoter, wherein the second promoter is the same or different from the first promoter.

354. (New) The vector of claim 352, wherein the antigen is a cancer antigen.

355. (New) The vector of claim 354, wherein the cancer antigen is EpCam/KSA.

356. (New) The vector of claim 355, wherein the expression vector comprises the vector shown in Figure 22B.

357. (New) A host cell transformed by a vector of claim 348.

358. (New) A vector comprising a nucleic acid of claim 325.

359. (New) The vector of claim 358, wherein the vector comprises a viral vector.

360. (New) The vector of claim 358, wherein the vector is an expression vector.

361. (New) The vector of claim 360, wherein the nucleic acid is operably linked to a promoter.

B1
cont
362. (New) The vector of claim 360, wherein the vector further comprises a polynucleotide sequence encoding an antigen.

363. (New) The vector of claim 362, wherein the nucleic acid is operably linked to first promoter and the polynucleotide sequence encoding the antigen is operably linked to a second promoter, wherein the second promoter is the same or different from the first promoter.

364. (New) The vector of claim 362, wherein the antigen is a cancer antigen.

365. (New) The vector of claim 364, wherein the cancer antigen is EpCam/KSA.

366. (New) The vector of claim 365, wherein the expression vector comprises the vector shown in Figure 22B.

367. (New) A host cell transformed by a vector of claim 358.

368. (New) A polypeptide which is specifically bound by a polyclonal antisera raised against the polypeptide of claim 259.

369. (New) An antibody or antisera which specifically binds a polypeptide of claim 259.

370. (New) A method of producing a polypeptide, the method comprising:

(a) introducing into a population of cells a nucleic acid of claim 302, the nucleic acid operatively linked to a regulatory sequence effective to produce the encoded polypeptide;

(b) culturing the cells in a culture medium to produce the polypeptide; and

(c) isolating the polypeptide from the cells or from the culture medium.

371. (New) A method of producing a polypeptide, the method comprising:

(a) introducing into a population of cells the expression vector of claim 350;

(b) administering the expression vector into a mammal; and

(c) isolating the polypeptide from the mammal or from a byproduct of the mammal.

372. (New) A method of producing a polypeptide, the method comprising:

(a) introducing into a population of cells the expression vector of claim 358;

(b) administering the expression vector into a mammal; and

(c) isolating the polypeptide from the mammal or from a byproduct of the mammal.

B)
cont

373. (New) A method for modulating an immune response in a mammal, the method comprising administering to cells of the mammal a nucleic acid of claim 302, wherein the nucleic acid is operably linked to a promoter, in an amount sufficient that sufficient expression of the encoded polypeptide results, to modulate an immune response in the mammal.

374. (New) The method of claim 373, further comprising administering to cells of the mammal a polynucleotide encoding an antigen specific for a disease or disorder, wherein the polynucleotide is operably linked to a promoter, in an amount sufficient that sufficient expression of the encoded polypeptide results, such that the nucleic acid modulates the immune response induced by the antigen.

375. (New) The method of claim 374, wherein the nucleic acid enhances the immune response induced by the antigen.

376. (New) The method of claim 373, wherein the nucleic acid is administered in vivo to the mammal.

377. (New) The method of claim 373, wherein the nucleic acid is administered in vitro or ex vivo to cells of the mammal.

378. (New) The method of claim 374, wherein the antigen is a cancer antigen.

379. (New) A method for inducing a T-cell proliferation response in a mammal, the method comprising administering to the mammal a nucleic acid of claim 302, wherein the nucleic acid is operably linked to a promoter, in an amount sufficient that sufficient expression of the encoded polypeptide results, to induce the T-cell proliferation response in the mammal.

(B) *cm*
380. (New) A method for inducing an effective immune response to an antigen in a mammal, the method comprising administering to a mammal, which mammal is exposed to the antigen, a polynucleotide comprising a nucleic acid of claim 302, wherein the nucleic acid is operably linked to a promoter, in an amount sufficient that sufficient expression of the encoded polypeptide results, to induce an effective immune response to the antigen.

381. (New) The isolated or recombinant nucleic acid of claim 325, wherein the polynucleotide sequence comprises at least nucleic acid residues 1-735 of SEQ ID NO:19.

These amendments are made without prejudice and are not to be construed as abandonment of the previously claimed subject matter. In accordance with the requirements of 37 C.F.R. § 1.121, a marked up version indicating deletion of all original claims 1-258 and showing the new claims is attached herewith as Appendix A. The set of new claims provided in Appendix A also constitutes a complete set and clean version of all currently pending claims.

REMARKS

Status of the Claims.

Claims 1-258 have been cancelled without prejudice to subsequent renewal in their original form or filing in a continuation or divisional application. New claims 259-381 have been added herein and are pending with entry of this amendment. New claims 259-381 introduce no new matter and support for the new claims is replete throughout the specification as filed. A detailed outline of support for each claim is shown below.

As explained in the present application, human B7-1 is a known co-stimulatory polypeptide that is typically expressed on antigen-presenting cells and mediates both positive and negative signals to T cells by binding to CD28 and CTLA-4 receptors expressed on T cells. Human B7-1 preferentially binds CTLA-4 receptor more strongly than it binds CD28 receptor. See, e.g., specification, page 2, lines 8-31; page 26, line 6 to page 27, line 16.